Security key
696389402
PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI)
CUSIP: 696389402
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.01 per share
- Shares outstanding
- 177,984,636
- Total 13F shares
- 135,909,594
- Share change
- +130,504,952
- Total reported value
- $319,442,849
- Price per share
- $2.35
- Number of holders
- 87
- Value change
- +$306,785,730
- Number of buys
- 78
- Number of sells
- 2
Report period
Q4 2025
Institutions
87
Top holders
10
PALI full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
PALISADE BIO, INC. SEC filings
PALISADE BIO, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 696389402
Recent filing periods:
Top shareholders of PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
|
— |
10%
|
15,200,117
|
$29,184,225 | +$5,677,630 | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13D/G
|
— |
10%
|
14,885,421
|
$27,835,737 | $0 | 28 Nov 2025 | |
| Octagon Capital Advisors LP |
13D/G
|
— |
6.4%
|
9,567,898
|
$18,370,364 | $0 | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
|
— |
6%
|
9,163,990
|
$21,358,511 | $0 | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
478,945
|
— | $0 | 30 Jun 2025 | |
| Squadron Capital Management LLC |
13D/G
|
Squadron Master Fund LP |
3%
|
4,500,000
|
$8,640,000 | -$7,200,000 | 31 Dec 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.02%
|
29,406
|
$25,280 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.01%
|
26,620
|
$22,884 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
19,413
|
$16,695 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.01%
|
14,085
|
$12,109 | — | 30 Sep 2025 | |
| NFSG Corp |
13F
|
Company |
0.01%
|
13,000
|
$11,176 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
8,618
|
$7,409 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
5,396
|
$4,639 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
2,347
|
$2,018 | — | 30 Sep 2025 | |
| Rockefeller Capital Management L.P. |
13F
|
Company |
0%
|
500
|
$430 | — | 30 Sep 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
100
|
$86 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
86
|
$73 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
21
|
$18 | — | 30 Sep 2025 | |
| Yuma Regional Medical Center |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,814,375
|
$925,331 | — | 19 Aug 2021 | |
| Thomas Hallam |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
137,592
mixed-class rows
|
$29,372 | — | 16 Aug 2022 | |
| Michael John Dawson |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
15,000
|
$7,650 | — | 29 Mar 2022 | |
| Cristina Csimma |
3/4/5
|
Director |
—
mixed-class rows
|
19,742
mixed-class rows
|
$5,609 | — | 08 Feb 2024 | |
| Stephanie Diaz |
3/4/5
|
Director |
—
mixed-class rows
|
19,680
mixed-class rows
|
$5,582 | — | 08 Feb 2024 | |
| James R. Neal |
3/4/5
|
Director |
—
mixed-class rows
|
17,800
mixed-class rows
|
$4,762 | — | 09 Feb 2024 | |
| Robert J. Trenschel |
3/4/5
|
Director |
—
mixed-class rows
|
17,800
mixed-class rows
|
$4,762 | — | 08 Feb 2024 | |
| Binxian Wei |
3/4/5
|
Director |
—
mixed-class rows
|
80,255
mixed-class rows
|
$4,158 | — | 06 Oct 2025 | |
| Mary Ann Gray |
3/4/5
|
Director |
—
mixed-class rows
|
12,700
mixed-class rows
|
$2,968 | — | 21 Nov 2023 | |
| Robert Curtis McRae |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
2,588
mixed-class rows
|
$1,320 | — | 03 Apr 2023 | |
| Emil Chuang |
3/4/5
|
Director |
—
mixed-class rows
|
87,400
mixed-class rows
|
— | — | 06 Oct 2025 | |
| Margery B. Fischbein |
3/4/5
|
Director |
—
class O/S missing
|
2,100
|
— | — | 11 Jul 2024 |
Institutional Holders of PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) as of Q4 2025
As of 31 Dec 2025,
PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
135,909,594 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Commodore Capital LP, JANUS HENDERSON GROUP PLC, Point72 Asset Management, L.P., Octagon Capital Advisors LP, RA CAPITAL MANAGEMENT, L.P., AMERIPRISE FINANCIAL INC, Eversept Partners, LP, FRANKLIN RESOURCES INC, and Boxer Capital Management, LLC.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
12
Q4 2025 holders
87
Holder diff
75
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.